4.4 Article

Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

期刊

CURRENT ONCOLOGY
卷 29, 期 3, 页码 1828-1839

出版社

MDPI
DOI: 10.3390/curroncol29030150

关键词

non-small cell lung cancer; lung cancer; screening; immunotherapy; iRAE; iRAEs; CAGPO; Canadian Association of General Practitioners in Oncology; ALK; EGFR; K-RAS; KRAS

类别

向作者/读者索取更多资源

This article presents a comprehensive review of the current best practices in the treatment of non-small cell lung cancer in Canada, covering screening, management of early stage and locally-advanced disease, as well as management of patients with metastatic disease. It also focuses on the incorporation of immunotherapy into practice and its associated toxicities.
Lung cancer is the leading cause of cancer death in Canada and a significant cause of morbidity for patients and their loved ones. There have been rapid advances in preventing, screening and treating this disease. Here, we present a contemporary review of treatment of non-small cell lung cancer in Canada based on current best practices. The focus of this review is to highlight recent data in screening for lung cancer, management of patients with early and locally-advanced non-small cell lung cancer, as well as management of patients with metastatic disease. There is a special focus on the incorporation of immunotherapy into practice and its associated toxicities.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据